title: In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.
abstract: ING-1(heMAb), a Human Engineered monoclonal antibody to epithelial cell adhesion molecule (Ep-CAM), was evaluated for its in vitro and in vivo activity. The dissociation constant of ING-1(heMAb) for binding to Ep-CAM on HT-29 human colon tumor cells was 2 to 5 nM, similar to chimeric ING-1. In antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity assays, ING-1(heMAb) caused a concentration-dependent lysis of BT-20 breast, MCF-7 breast, HT-29 colon, and CACO-2 colon tumor cells, with maximum cytolysis at approximately 1 microg/ml. After an intravenous injection in rats, plasma ING-1(heMAb) levels declined with an alpha half-life of 8 to 11 hours, and a beta half-life of 20 days, typical of an IgG in a species without the target for ING-1. In nude mice with human HT-29 colon tumors, plasma ING-1(heMAb) levels declined more rapidly than in non-tumor-bearing mice, suggesting an enhanced clearance via the tumor-associated human Ep-CAM. In nude mice, intravenous treatments with ING-1(heMAb) twice a week for 3 weeks significantly suppressed the growth of human HT-29 colon and PC-3 prostate tumors in a dose-dependent manner, with 1.0 mg/kg providing the greatest benefit. These results indicate that Human Engineered ING-1(heMAb) is a high-affinity antibody with potent in vitro activity that targets and suppresses the growth of human tumors in vivo.
authors.affiliation: Department of Pharmacology, XOMA (US) LLC, Berkeley, CA 94710, USA. ammons@xoma.com
authors.forename: W Steve
authors.initials: WS
authors.lastname: Ammons
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Bauer
authors.forename: Arnold H
authors.initials: AH
authors.lastname: Horwitz
authors.forename: Zhi J
authors.initials: ZJ
authors.lastname: Chen
authors.forename: Eddie
authors.initials: E
authors.lastname: Bautista
authors.forename: Harry H
authors.initials: HH
authors.lastname: Ruan
authors.forename: Marina
authors.initials: M
authors.lastname: Abramova
authors.forename: Kristen R
authors.initials: KR
authors.lastname: Scott
authors.forename: Russell L
authors.initials: RL
authors.lastname: Dedrick
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry*; D000951:Antigens, Neoplasm / Q000737:chemistry* / Q000276:immunology; D002448:Cell Adhesion; D015815:Cell Adhesion Molecules / Q000737:chemistry* / Q000276:immunology; D045744:Cell Line, Tumor; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D000071858:Epithelial Cell Adhesion Molecule; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry; D007700:Kinetics; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011485:Protein Binding; D051381:Rats; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; C479480:ING-1 monoclonal antibody, human; D007074:Immunoglobulin G